Hunter Syndrome Therapeutics Market Report 2026

Hunter Syndrome Therapeutics Market Overview

• Hunter Syndrome Therapeutics market size has reached to $1.24 billion in 2025 • Expected to grow to $1.78 billion in 2030 at a compound annual growth rate (CAGR) of 7.6% • Growth Driver: The Increasing Healthcare Investment In Rare Diseases Fuels The Market Growth Due To Rising Unmet Medical Needs • Market Trend: Advancements In Targeted Therapies Improving Neurological And Systemic Outcomes In Rare Genetic Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hunter Syndrome Therapeutics Market?

Hunter syndrome therapeutics refer to medical treatments developed to manage hunter syndrome (mucopolysaccharidosis II), a rare X-linked genetic disorder caused by deficiency of the enzyme iduronate-2-sulfatase. These therapeutics are designed to address the underlying biochemical imbalance, slow disease progression, and manage clinical manifestations through advanced pharmaceutical and biotechnology-based interventions. They focus on improving patient outcomes by targeting disease mechanisms at the molecular level and providing long-term disease management solutions. The main therapy types of hunter syndrome therapeutics include enzyme replacement therapy, hematopoietic stem cell transplant, gene therapy, substrate reduction therapy, and other therapy types. Enzyme replacement therapy refers to a treatment approach that supplies the deficient iduronate-2-sulfatase enzyme to help manage the symptoms and progression of Hunter syndrome. These therapies are used across disease severities including mild Hunter syndrome, moderate Hunter syndrome, and severe Hunter syndrome and are designed for pediatric, adolescent, and adult patients. They are administered through intravenous, oral, and others and are utilized by end users including hospitals, specialty clinics, and others.

What Is The Hunter Syndrome Therapeutics Market Growth Forecast?

The hunter syndrome therapeutics market size is expected to see strongly grown in the next few years. It will grow to $1.78 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to advancement of gene therapy platforms for hunter syndrome treatment, increasing adoption of precision medicine approaches, expansion of newborn screening initiatives for early detection, growing pipeline of next generation therapeutic candidates, rising collaborations between biotechnology companies and research institutions. Major trends in the forecast period include increasing adoption of enzyme replacement therapies for long term disease management, growing clinical development of gene therapies targeting iduronate-2-sulfatase deficiency, rising focus on early diagnosis and newborn screening programs for hunter syndrome, expanding use of personalized treatment approaches based on disease severity, increasing investments in rare disease research and orphan drug development.

Global Hunter Syndrome Therapeutics Market Segmentation

1) By Therapy Type: Enzyme Replacement Therapy; Hematopoietic Stem Cell Transplant; Gene Therapy; Substrate Reduction Therapy; Other Therapy Types 2) By Disease Severity: Mild Hunter Syndrome; Moderate Hunter Syndrome; Severe Hunter Syndrome 3) By Age Group: Pediatric; Adolescent; Adult 4) By Route Of Administration: Intravenous; Oral; Other Route Of Administrations 5) By End User: Hospitals; Specialty Clinics; Other End Users Subsegments: 1) By Enzyme Replacement Therapy: Recombinant Enzyme Replacement Therapy; Intravenous Enzyme Replacement Therapy; Long Acting Enzyme Replacement Therapy; Targeted Enzyme Replacement Therapy 2) By Hematopoietic Stem Cell Transplant: Allogeneic Hematopoietic Stem Cell Transplant; Autologous Hematopoietic Stem Cell Transplant; Cord Blood Hematopoietic Stem Cell Transplant; Matched Donor Hematopoietic Stem Cell Transplant 3) By Gene Therapy: In Vivo Gene Therapy; Ex Vivo Gene Therapy; Viral Vector Based Gene Therapy; Non Viral Gene Therapy 4) By Substrate Reduction Therapy: Small Molecule Substrate Reduction Therapy; Oral Substrate Reduction Therapy; Combination Substrate Reduction Therapy; Targeted Substrate Reduction Therapy 5) By Other Therapy Types: Symptomatic Management Therapy; Supportive Care Therapy; Combination Therapeutic Approaches; Emerging Experimental Therapies

What Is The Driver Of The Hunter Syndrome Therapeutics Market?

The increasing healthcare investment in rare diseases is expected to propel the growth of the hunter syndrome therapeutics market going forward. Rare diseases refer to disorders that affect fewer than 1 in 2,000 people, often involving complex symptoms and limited treatment options. Healthcare investment in rare diseases is rising due to increasing government incentives such as orphan drug policies, tax credits, and regulatory support, which encourage pharmaceutical companies to invest in the development of treatments for small and underserved patient populations. Healthcare investment in rare diseases drives the development of hunter syndrome therapeutics by providing funding, regulatory incentives, and research support that enable the advancement, clinical testing, and commercialization of enzyme replacement therapies and gene therapies for this rare genetic disorder with limited treatment options. For instance, in April 2024, according to Global Genes, a US-based nonprofit organization, in the first quarter of 2024, companies developing drugs for rare diseases raised $7.1 billion through public equity and debt financings, a 307% surge compared to the $1.8 billion raised in the same period of 2023. Therefore, the increasing healthcare investment in rare diseases is driving the growth of the hunter syndrome therapeutics industry.

Key Players In The Global Hunter Syndrome Therapeutics Market

Major companies operating in the hunter syndrome therapeutics market are Takeda Pharmaceutical Company Limited; Denali Therapeutics Inc.; Sanofi S.A.; GC Biopharma Corporation; Ultragenyx Pharmaceutical Inc.; JCR Pharmaceuticals Co. Ltd.; REGENXBIO Inc.

Global Hunter Syndrome Therapeutics Market Trends and Insights

Major companies operating in the hunter syndrome therapeutics market are focusing on developing innovative therapies, such as blood-brain barrier-crossing biologic therapy to improve neurological drug delivery, reduce disease progression, and enhance treatment outcomes in patients with Hunter syndrome. Blood-brain barrier-crossing biologic therapy is an advanced treatment that delivers therapeutic agents across the blood-brain barrier into the brain, helping improve neurological symptoms, slow disease progression, and enhance overall treatment outcomes in central nervous system disorders. For instance, in March 2026, Denali Therapeutics Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration approval for Avlayah (tividenofusp alfa-eknm), a novel therapy for treating certain neurologic manifestations of Hunter syndrome (MPS II). The treatment is designed to cross the blood-brain barrier using advanced transport technology, enabling targeted enzyme delivery to affected tissues in the central nervous system and peripheral organs. It is intended to reduce glycosaminoglycan accumulation, improve neurological function, and address both cognitive and systemic symptoms associated with the disease, marking a significant advancement in rare disease therapeutic innovation.

What Are Latest Mergers And Acquisitions In The Hunter Syndrome Therapeutics Market?

In May 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired AVROBIO Inc.’s investigational cystinosis gene therapy program for $87.5 million. With this acquisition, Novartis AG aims to strengthen its rare disease and gene therapy pipeline by adding a late-stage hematopoietic stem cell-based treatment for cystinosis, thereby expanding its capabilities in innovative genetic medicine targeting rare metabolic disorders. AVROBIO Inc. is a US-based clinical-stage biotechnology company that specializes in developing gene and cell therapies for one-time lentiviral gene therapy (AVR-RD-05) for hunter syndrome (MPS II).

Regional Outlook

North America was the largest region in the hunter syndrome therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hunter Syndrome Therapeutics Market?

The hunter syndrome therapeutics market consists of sales of prescription medicines, biologic formulations, and supportive treatment drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and healthcare providers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hunter Syndrome Therapeutics Market Report 2026?

The hunter syndrome therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hunter syndrome therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.